Takeda invests $125m in Maverick T-cell platform partnership

pharmafile | January 12, 2017 | News story | Research and Development Maverick, Takeda 

Takeda has announced its intention to invest $125 million in a partnership with Maverick Therapeutics to develop the latter’s T-cell engagement platform.

Maverick’s platform is designed to improve T-cell redirection therapy as a cancer treatment. The $125 million invested breaks down to include an upfront option, equity and R&D funding; the deal also gives Takeda the right to purchase Maverick after five years. Former Pfizer executive and President and CSO of Maverick Hans-Peter Gerber will head up the new management team at the company.

“We see significant potential in Maverick to develop unique, small and customizable T-cell engagement therapeutics,” said Phil Rowlands, interim head, Oncology Therapeutic Area Unit at Takeda. “Collaborations are critical to helping us advance our aspiration of curing cancer. Working together with Maverick will enable us to leverage a potentially ground-breaking biologics platform to support Takeda’s goal of developing innovative, targeted therapies to treat people with cancer.”

“We believe that this collaboration validates Maverick’s approach to T-cell engagement in the tumour microenvironment which we believe will allow us to address previously intractable oncology targets,” said Jean-Marie Guenot, Maverick’s co-founder. “Importantly, this strong collaboration should allow us to move rapidly to the clinic and address unmet needs in cancer immunotherapy.”

Matt Fellows

Related Content

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which …

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …

Latest content